Please Wait

Applying Filters...

Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Cefepime Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

18 API Suppliers, 9 USDMF, 1 CEP/COS, 8 JDMF, 4 EU WC, 15 KDMF, 7 NDC API, 3 Listed Suppliers, $ API Reference Price

FINISHED DOSAGE FORMULATIONS

43 FDF Dossiers, 27 FDA Orange Book, 2 Europe, 3 Canada, 8 South Africa, 3 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Faran Shimi Pharmaceutical, 1 Pfanstiehl, 1 Actylis, 1 Pluviaendo, 4 Roquette

EXCIPIENTS BY APPLICATIONS

4 Parenteral, 2 Fillers, Diluents & Binders, 1 Thickeners and Stabilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 5 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 Regulatory FDF Prices

2 Regulatory FDF Prices

MARKET PLACE

7 APIs

7 APIs

PATENTS & EXCLUSIVITIES

24 Health Canada Patents

24 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 USP, 1 Others

$ Xls download

Filters

Log in to access your PharmaMiles and download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
28/03/2025	ACS DOBFAR SPA	Italy	ACS DOBFAR SPA	19798	CRUDE CEFEPIME HYDROCHLORIDE	2006-09-26	Active	II	N/A
28/03/2025	ACS DOBFAR SPA	Italy	ACS DOBFAR SPA	19927	CEFEPIME HYDROCHLORIDE ORAL GRADE	2006-11-01	Inactive	II	N/A

Contact us
to update this info

Cefepime Hydrochloride

Cefepime Hydrochloride

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

18 API Suppliers

9 USDMF

1 CEP/COS

8 JDMF

4 EU WC

15 KDMF

7 NDC API

3 Listed Suppliers

$ API Reference Price

FINISHED DOSAGE FORMULATIONS

43 FDF Dossiers

27 FDA Orange Book

2 Europe

3 Canada

8 South Africa

3 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Faran Shimi Pharmaceutical

1 Pfanstiehl

1 Actylis

1 Pluviaendo

4 Roquette

EXCIPIENTS BY APPLICATIONS

4 Parenteral

2 Fillers, Diluents & Binders

1 Thickeners and Stabilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

5 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 Regulatory FDF Prices

MARKET PLACE

7 APIs

PATENTS & EXCLUSIVITIES

24 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 USP

1 Others

Filters

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons